Glaxo buys rights to experimental diabetes drug Drug maker GlaxoSmithKline, which has co-US headquarters in Philadelphia and Research Triangle Park, has acquired exclusive rights to a potential diabetes treatment in a deal that could be worth more than \$180 million.